Jinhe Li
Shanghai Green Valley Pharmaceuticals
Dr. Jinhe Li is the CEO of Shanghai Green Valley Pharmaceuticals and a Lefler Scholar at Harvard Medical School, while also serving as Director of the Joint Lab of Large-scale Intelligence Model of Neuromedicine at the Guangdong Institute of Intelligent Science and Technology. After receiving his Ph.D. in Biochemistry and Molecular Biology from the State University of New York, where he studied gene regulation, he completed his postdoctoral fellowship in Neurobiology at Harvard Medical School, focusing on Alzheimer's disease research. His career in pharmaceutical research includes roles as Principal Investigator at Pfizer, where he worked on discovering drug targets for Alzheimer's disease genes, and as Principal Investigator and Business Development Director at Abbott (now Abbvie), where he led the development of Alzheimer's disease therapies. A standing member of the National Institutes of Health (NIH) Review Panel for Alzheimer's disease and CNS disorders, Dr. Li is notably credited with the discovery of the Alzheimer's disease gene PS2 and its related gene Pen-2.
